Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid. Issue 11 (1st November 2020)

• Record Type: Journal Article
• Authors: Gao, Yue; Zhang, Shujun; Li, Jiajun; Zhao, Jinqiu; Xiao, Qing; Zhu, Yali; Zhang, Jia; Huang, Wenxiang
• Is Part Of: Bioscience, biotechnology, and biochemistry. Volume 84:Issue 11(2020)
• Page Start: 2228
• Page End: 2240
• Publication Date: 2020-11-01
• Subjects: Ginsenoside Rg1 -- nonalcoholic fatty liver disease -- lipid metabolism -- hepatic steatosis; Biotechnology -- Periodicals; Biochemistry -- Periodicals; 660.6
• DOI: 10.1080/09168451.2020.1793293
• Languages: English
• ISSNs: 0916-8451

Abstract

ABSTRACT: Ginsenoside Rg1 (G-Rg1) is a bioactive phytochemical that has been found to be beneficial for the treatment of several diseases including nonalcoholic fatty liver disease (NAFLD). But there is a lack of literature reporting the effect of G-Rg1 on lipid metabolism balance in NAFLD. We investigated the effect and mechanism of G-Rg1 on lipid metabolism in vitro . We found that G-Rg1 decreased the levels of TG, TC, and MDA, and increased activity of SOD. Results of RT-PCR and western blotting showed that supplementation with G-Rg1 downregulated the expression of PPAR γ, FABP1, FATP2/5, CD36, SREBP1 c, and FASN, while the expression of PPAR ɑ, CPT1, ACOX1, MTTP, and ApoB100 was upregulated, after induction by a free fatty acid. Taken together, we conclude that G-Rg1 inhibits lipid synthesis and lipid uptake, and enhances lipid oxidation and lipid export to reduce hepatic steatosis of HepG2 cells by regulating PPAR ɑ and PPAR γ expression. Graphical abstract: uf0001 The pathway of G-Rg1 ameliorate lipid accumulation in hepatocytes in vitro .